The use of dual antiplatelet therapy for the first three-six months after transcatheter aortic valve implantation (TAVI) has beensuggested.[1,2] However, the additional benefit of anticoagulant therapy during the same period has conflicting data and even the guidelines from different cardiology societies are not in line;the American College of Cardiology/American Heart Association Guidelines recommend with an indication class Ⅱb the use of vitamin K anticoagulants with an international normalized ratio (INR) of 2.5 for the first three-months post-TAVI alongside with aspirin to avoid thromboembolic events, while the European Association of Cardiology Guidelines do not[1,2] This case report presents a thromboembolic event in the coronary arteries leading to myocardial infarction and death post-TAVI, diagnosed on autopsy by identifying the thrombi on the CoreValve stent.